SNS Financial Group’s Evogene EVGN Stock Holding History

SNS Financial Group’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,000	Closed	-$8.4K	–	192
2023 Q4	$8.4K	Hold	1,000	–	–	﹤0.01%	187
2023 Q3	$5.87K	Hold	1,000	–	–	﹤0.01%	181
2023 Q2	$10.7K	Hold	1,000	–	–	﹤0.01%	186
2023 Q1	$6.3K	Hold	1,000	–	–	﹤0.01%	183
2022 Q4	$7K	Hold	1,000	–	–	﹤0.01%	198
2022 Q3	$8K	Hold	1,000	–	–	﹤0.01%	191
2022 Q2	$8K	Hold	1,000	–	–	﹤0.01%	198
2022 Q1	$13K	Hold	1,000	–	–	﹤0.01%	223
2021 Q4	$16K	Hold	1,000	–	–	﹤0.01%	241
2021 Q3	$26K	Hold	1,000	–	–	﹤0.01%	223
2021 Q2	$34K	Buy	+1,000	New	+$39.2K	﹤0.01%	220

Other funds holding EVGN

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

SNS Financial Group's EVGN Position: Q1 2024 in Review

SNS Financial Group sold out of Evogene (EVGN) in Q1 2024, closing a stake of 1,000 shares — an estimated $8.4K sold.

SNS Financial Group first reported a position in EVGN in Q2 2021 and held it in 11 quarters. The position peaked at $34K in Q2 2021. 29 funds tracked by Wall St. Rank hold EVGN as of Q1 2024.

SNS Financial Group reported no remaining Evogene position as of Q1 2024 after selling out during the quarter.
SNS Financial Group sold 1,000 Evogene shares in Q1 2024, an estimated $8.4K.
SNS Financial Group first reported a position in Evogene in Q2 2021 and held it in 11 quarters.
SNS Financial Group's Evogene position peaked at $34K in Q2 2021.
29 funds tracked by Wall St. Rank held Evogene as of Q1 2024.

Based on SNS Financial Group's 13F filing for Q1 2024, filed 24 Apr 2024.